Table 3 Prevalence of CTC graded GI and GU toxicities
From: Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)
Toxicity | Grade | Start | 1 | 3 | 6 | 9 | 12 | 18 | 24 |
|---|---|---|---|---|---|---|---|---|---|
Diarrhea | 0 | 100% | 53% | 84% | 75% | 83% | 88% | 94% | 94% |
1 | 0% | 35% | 16% | 23% | 15% | 12% | 6% | 6% | |
2 | 0% | 12% | 0% | 2% | 2% | 0% | 0% | 0% | |
Proctitis | 0 | 86% | 79% | 93% | 92% | 100% | 98% | 100% | 100% |
1 | 14% | 21% | 7% | 8% | 0% | 2% | 0% | 0% | |
2 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
Rectal Bleeding | 0 | 100% | 91% | 95% | 100% | 98% | 98% | 96% | 96% |
1 | 0% | 9% | 5% | 0% | 2% | 2% | 4% | 4% | |
2 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
Highest GI | 0 | 67% | 46% | 77% | 75% | 82% | 86% | 91% | 91% |
1 | 33% | 42% | 23% | 23% | 16% | 14% | 9% | 9% | |
2 | 0% | 12% | 0% | 2% | 2% | 0% | 0% | 0% | |
Hematuria | 0 | 98% | 95% | 93% | 94% | 91% | 90% | 91% | 94% |
1 | 2% | 5% | 4% | 2% | 4% | 4% | 7% | 2% | |
2 | 0% | 0% | 4% | 2% | 4% | 4% | 0% | 2% | |
3 | 0% | 0% | 0% | 2% | 2% | 2% | 2% | 2% | |
Dysuria | 0 | 89% | 65% | 77% | 90% | 80% | 92% | 91% | 92% |
1 | 11% | 35% | 23% | 10% | 20% | 8% | 9% | 8% | |
2 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
Incontinence | 0 | 75% | 67% | 71% | 79% | 74% | 77% | 76% | 73% |
1 | 21% | 30% | 27% | 17% | 24% | 21% | 19% | 27% | |
2 | 4% | 4% | 2% | 4% | 2% | 2% | 6% | 0% | |
Urinary frequency/ urgency | 0 | 39% | 16% | 55% | 62% | 48% | 52% | 48% | 58% |
1 | 61% | 82% | 45% | 35% | 50% | 44% | 48% | 42% | |
2 | 0% | 2% | 0% | 4% | 2% | 4% | 4% | 0% | |
Retention | 0 | 67% | 33% | 57% | 54% | 57% | 56% | 54% | 44% |
1 | 33% | 26% | 20% | 21% | 19% | 15% | 19% | 29% | |
2 | 0% | 53% | 29% | 30% | 29% | 31% | 31% | 36% | |
3 | 0% | 0% | 0% | 0% | 0% | 2% | 2% | 2% | |
Highest GU | 0 | 33% | 5% | 25% | 32% | 26% | 32% | 32% | 37% |
1 | 63% | 53% | 51% | 46% | 49% | 42% | 39% | 35% | |
2 | 10% | 89% | 50% | 40% | 46% | 42% | 44% | 39% | |
3 | 0% | 0% | 0% | 2% | 2% | 2% | 4% | 4% |